Cara Therapeutics | CARA - Operating Profit


Cara Therapeutics reported $-5.94M in Operating Profit for its fiscal quarter ending in September of 2025.





Operating Profit Change Date
Acadia Pharmaceuticals USD -4.62M 22.01M Mar/2026
Alterity Therapeutics Limited AUD -8.07M 302.4K Dec/2025
Assertio Holdings USD -3.05M 569K Sep/2024
Cara Therapeutics USD -5.94M 3.55M Sep/2025
Cassava Sciences USD -13.55M 1.69M Dec/2025
Chugai Pharma JPY 158.77B 10.24B Mar/2026
Cipla INR 6.14B 3.63B Mar/2026
Clal Biotechnology ILS -1.74M 7.46M Dec/2022
Compugen USD 56.04M 63.93M Dec/2025
CSL USD 2.64B 1.97B Dec/2025
Grifols EUR 320.55M 91.01M Dec/2025
Halozyme Therapeutics USD -61.77M 26.64M Mar/2026
J&J USD 6.62B 1.03B Mar/2026
Neurocrine Biosciences USD 214.6M 13.3M Mar/2026
Pacira USD 4.62M 1.43M Mar/2026
Pfizer USD 4.99B 340M Mar/2026
RedHill Biopharma USD -4.22M 1.8M Jun/2024
Supernus Pharmaceuticals USD -35.25M 49.07M Mar/2026
Vanda Pharmaceuticals USD -40.66M 29.66M Dec/2024